Limited Competition for the Continuation of Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01 Clinical Trial Optional)

The summary for the Limited Competition for the Continuation of Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition for the Continuation of Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01 Clinical Trial Optional): The primary purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite applications from the clinical sites that have participated in the NIDDK Gastroparesis Clinical Research Consortium (GPRCR), to support the ongoing GPCRC cohorts, including the first U.S. registry of children and adolescents with gastroparesis, to support ongoing clinical trials and to provide a platform for informative ancillary studies. In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of bio-specimens (blood stools and when feasible gastric tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection as well as to build on the ongoing Pathological Basis of gastroparesis study which will increase understanding of the pathological basis of gastroparesis.

Federal Grant Title:	Limited Competition for the Continuation of Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-20-504
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	December 16th, 2020
Original Application Deadline:	December 16th, 2020
Posted Date:	September 24th, 2020
Creation Date:	September 24th, 2020
Archive Date:	January 21st, 2021
Total Program Funding:
Maximum Federal Grant Award:	$250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 25th, 2020

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-504.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...; • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...; • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...; • Diabetes Research Centers (P30 Clinical Trial Optional); • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed); • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required); • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...; • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...